GLP3 (RETA) 10MG
RETA is a synthetic peptide known as a triple-receptor agonist, designed to target the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. In laboratory research, it is utilized to investigate the coordinated regulation of glucose homeostasis, lipid metabolism, and energy expenditure through simultaneous multi-pathway signaling. For research use only.
- Triple-Agonist Metabolic Research: Investigated for its ability to activate three distinct incretin and metabolic receptors simultaneously to evaluate synergistic effects on energy balance.
- Energy Expenditure Studies: Studied for the role of glucagon receptor agonism in increasing resting energy expenditure and thermogenesis in animal models.
| Aspect | Details |
|---|---|
| Drug Class | Triple GLP-1 / GIP / glucagon receptor agonist (first-in-class triple incretin mimetic) |
| Mechanism of Action | Activates GLP-1 (appetite suppression, glucose control, gastric emptying delay), GIP (enhanced insulin secretion, metabolic synergy), and glucagon receptors (increased energy expenditure/fat burning, liver fat reduction, further appetite/energy regulation). This multi-target approach leads to greater weight loss, thermogenesis, and metabolic improvements than dual or single agonists. |
| Administration | Subcutaneous injection (once weekly) |
| FDA Status (March 2026) | Investigational / Not approved. Phase 3 TRIUMPH program ongoing (multiple trials); TRIUMPH-4 topline released Dec 2025. Full Phase 3 readouts expected throughout 2026; potential NDA submission late 2026–early 2027, approval possibly late 2027 or later. Not available by prescription outside trials/compounded (grey-market risks high). |
| Dosing (in Trials) | Escalation starts low (e.g., 2 mg or 4 mg initial); maintenance: 4 mg, 8 mg, 9 mg, or 12 mg weekly (highest doses in Phase 3: 9 mg and 12 mg). Dose-dependent efficacy and side effects. |
| Key Clinical Trials & Weight Loss Efficacy | – Phase 2 (NEJM 2023, 48 weeks): Up to 24.2% mean body weight loss (12 mg dose) vs. ~2% placebo. – Phase 3 TRIUMPH-4 (topline Dec 2025, 68 weeks, obesity + knee OA, no diabetes): Up to 28.7% mean loss (12 mg; ~71.2 lbs / 32.3 kg from baseline ~248 lbs); 26.4% at 9 mg. ~58% achieved ≥25% loss, many ≥30–35%. Placebo ~2%. Superior to prior incretins. – Additional benefits: Up to 75.8% reduction in knee OA pain (WOMAC score), liver fat clearance (earlier data up to 82%). |
| Additional Benefits | Highest reported weight loss in trials; potent liver fat reduction (MASLD/MASH potential); knee OA pain relief; cardiometabolic improvements (BP, lipids); energy expenditure boost; potential for OSA, CVD, and other obesity complications (ongoing TRIUMPH trials). |
| Common Side Effects | Gastrointestinal (dose-related): nausea, vomiting, diarrhea, constipation (mostly mild-moderate, transient during escalation; mitigated by slow titration). Dose-dependent heart rate increase (peaks early, declines). |
| Serious/Rare Risks | Similar to incretins: pancreatitis, gallbladder issues possible. New signal in TRIUMPH-4: dysesthesia (abnormal/painful touch sensation) in 8.8–20.9% (dose-dependent; 0.7% placebo). High discontinuation rates (12–18% due to AEs, including perceived excessive weight loss). Thyroid concerns (rodent data, low human risk). |
| Typical Use Context | Emerging as potentially most potent for severe obesity, metabolic disorders, and complications (e.g., OA pain, liver disease). Still experimental; research focus on superior efficacy vs. semaglutide/tirzepatide. |
| Notes | Weight loss dose-dependent and sustained with continuation (regain likely on withdrawal). Tolerability challenges at high doses (higher discontinuations). Seven more Phase 3 TRIUMPH readouts expected in 2026. For research use only in non-trial settings—impurities/legality risks in grey market. |
Moses –
this shit is making miracles, dont think buy it
Fabiano –
best decision ever, lost like 18kg in 3 months
Rico –
PenformTM Retatrutide got me down 50 lbs already. No cap, this triple beast outperforms tirz easy—energy high, appetite ghosted. Thursday order, Saturday delivery—fast and ghost mode discreet. Worth every penny.
Sabrina –
Top product, fast delivery
Suarez –
This Retatrutide vial bangs harder than semaglutide or tirzepatide. Dropped 38 lbs quick, cravings dead, actually feel the burn. Ordered Tuesday, hit my door Thursday—fast AF and lowkey discreet. PenformTM got the sauce for real.
Best –
PenformTM Retatrutide got me down 50 lbs already. No cap, this triple beast outperforms tirz easy—energy high, appetite ghosted. Thursday order, Saturday delivery—fast and ghost mode discreet. Worth every penny.
Adam –
No problem, good communication, top tier team